Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for BDX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Becton Dickinson & Co ranked in the 38th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Becton Dickinson & Co ended up being:
Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
The weighted average cost of capital for the company is 7. This value is greater than only 11.93% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
HBIO, TARO, ITGR, USPH, and AMED can be thought of as valuation peers to BDX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NYSE: BDX shares. Investors, who purchased shares of Becton, Dickinson and Company (BDX), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On February 27, 2020, a lawsuit was filed against Becton, Dickinson and Company over alleged Securities Laws Violations.
DUBLIN, May 26, 2020 /PRNewswire/ -- The "Coronavirus Test Kits Market in North America 2020-2024" report has been added to ResearchAndMarkets.com's offering. The coronavirus test kits market in North America is poised to grow by $ 116.27 million during 2020-2024 progressing at a CAGR of…
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 11:00 a.m. ET.